Fig. 1: PFS in the ITT population and in patient subgroups based on prior treatment. | Leukemia

Fig. 1: PFS in the ITT population and in patient subgroups based on prior treatment.

From: Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study

Fig. 1

PFS in (a) the ITT populationa and in patients with (b) one prior line of therapy, (c) responses of CR or better, (d) prior lenalidomide exposure, or (e) refractoriness to bortezomib. Kaplan–Meier estimates of PFS. PFS, progression-free survival; ITT, intent-to-treat; D-Rd, daratumumab/lenalidomide/dexamethasone; Rd, lenalidomide/dexamethasone; HR, hazard ratio; CI, confidence interval; NE, not estimable. aThe upper bound of the 95% CI is currently NE.

Back to article page